CSI Market
Sign In | Register

Provention Bio Inc (PRVB) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PRVB Annual Cash Flow →
Quarterly cash flow trends provide additional context on Provention Bio Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Operating Activities
Income-113.57
Depreciation & amortization0.60
Amortization of Other Assets0.87
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.23
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation19.03
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Noncash Operating Lease Expense-0.05
Increase Decrease In Contract With Customer Liability0.92
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-1.35
Increase (Decrease) in Accounts Payable3.22
Increase (Decrease) in Accrued Liabilities7.08
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.07
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.21
Discontinued operations0.00
Net Cash flow from Operating Activities-75.41
Investing Activities
Capital Expenditures-15.80
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities30.75
Payments to Acquire Marketable Securities-103.08
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-88.13
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings23.71
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock58.26
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Deferred Financing Costs Related To Initial Public Offering-
Proceeds From Atthemarket Stock Sales Net-
Proceeds From Issuance Sale Of Equity-
Proceeds From Atthemarket Stock Sales-
Proceeds From At The Market Stock Sales Net47.42
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities129.38
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-91.20
Total Cash Flow-34.15
4 historic quarters locked

Sign in to unlock the full Provention Bio Inc cash flow history.

Sign In Create Free Account

About Provention Bio Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-23-009516

Figures are derived from filed reports and may be restated. Historical data is subject to revision.